Neurocrine is Hiding Ingrezza Hospitalizations

Discussion in 'Neurocrine' started by anonymous, Aug 26, 2019 at 7:04 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Why isn't Neurocrine being proactive in informing their physicians that Ingrezza has hospitalized people? The FDA made Neurocrine add hopsitalizations to their PI and yet no one has informed me of this. Seems only certain physicians have been notified. The speakers.
     

  2. anonymous

    anonymous Guest

    Seems like it's all in print, so what's the problem?

    Parkinsonism: Cases of parkinson-like symptoms (eg, falls, gait disturbances, tremor, drooling, hypokinesia), some severe requiring hospitalization, have been reported. Onset of severe symptoms occurs most commonly within 2 weeks of the start of therapy or a dose increase; may resolve with discontinuation of therapy​
     
  3. anonymous

    anonymous Guest

    Yes all in print, but you are not informing your prescribers of the change. The company is in willfully not talking about it because they know that the providers do not routinely look up PI info on products they have been prescribing. No one knows about these severe reactions and hospitalizations. Neurocrine has an ethics problem but they will blame it on the prescribers for not knowing of a change that they ethically should be proactively talking to their prescribers about.
     
  4. anonymous

    anonymous Guest

    > Neurocrine has an ethics problem

    Interesting observation
     
  5. anonymous

    anonymous Guest

    Everyone who works here knows we have an ethics problem.
     
  6. anonymous

    anonymous Guest

    Everyone who doesn't work there knows it, too.
     
  7. anonymous

    anonymous Guest

    Do you work here?
    Do you have an ethics problem?
     
  8. anonymous

    anonymous Guest

    Trying to get another job to get away from this place.
     
  9. anonymous

    anonymous Guest

    Let me guess... East zone??
     
  10. anonymous

    anonymous Guest

    You are real genius. Now go back to convincing your providers into writing a product that hospitalizes their patients.
     
  11. anonymous

    anonymous Guest

    Strangely enough, they just keep writing it. Go back to trying to compete buddy. On the Neurocrine page desperately trying to figure out why you keep losing.
     
  12. anonymous

    anonymous Guest

    Who's ethics apply here?
     
  13. anonymous

    anonymous Guest

    Keep hiding your data from the prescribers. Works great until it doesn't.
     
  14. anonymous

    anonymous Guest

    Look we have a quota to meet. If the doctors don't stay up to date on the drugs they prescribe it's not our problem. The information is their for them to read in the updated PI. If they don't care about causing Parkinsonism in their patients or hospitalizing them, it's on them.
     
  15. anonymous

    anonymous Guest

    Prime example of the ethics problem here. Get the prescriptions at any cost. This will come back to bite us!
     
  16. anonymous

    anonymous Guest

    What about the hypersensitivity reactions?Alergic dermatitis, angioedema, pruritis, and urticaria - oh my!
     
  17. anonymous

    anonymous Guest

    Sounds like possible liver damage. Before long, falls won't be the only adverse event causing all those deaths.
     
  18. anonymous

    anonymous Guest

    Those 77 deaths are most likely from all the severe Parkinsonism that causes all the older TD sufferers to fall down and be hospitalized.
     
  19. anonymous

    anonymous Guest

    What is the North Seattle rep’s name?
     
  20. anonymous

    anonymous Guest


    The chick who used to sell Austedo and left Teva?